These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 30500627)

  • 1. Comparison of Clinical Outcomes between Endovascular Therapy with Self-Expandable Nitinol Stent and Femoral-Popliteal Bypass for Trans-Atlantic Inter-Society Consensus II C and D Femoropopliteal Lesions.
    Okuno S; Iida O; Iida T; Takahara M; Yamaoka T; Kitano I; Asai M; Masuda M; Okamoto S; Ishihara T; Nanto K; Kanda T; Tsujimura T; Matsuda Y; Mano T
    Ann Vasc Surg; 2019 May; 57():137-143. PubMed ID: 30500627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective Multicenter Comparison of S.M.A.R.T. CONTROL and MISAGO Stents in Treatment of Femoropopliteal Lesions.
    Suzuki K; Takahara M; Shintani Y; Tanaka A; Soga Y; Yamaoka T; Tosaka A; Sasaki S; Kawasaki D; Tsuchiya T; Kozuki A; Iida O
    J Vasc Interv Radiol; 2016 Nov; 27(11):1642-1649. PubMed ID: 27567999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shared and differential factors influencing restenosis following endovascular therapy between TASC (Trans-Atlantic Inter-Society Consensus) II class A to C and D lesions in the femoropopliteal artery.
    Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Nanto S; Uematsu M
    JACC Cardiovasc Interv; 2014 Jul; 7(7):792-8. PubMed ID: 25060024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of intravascular ultrasound in femoropopliteal stenting for peripheral artery disease with TASC II class A to C lesions.
    Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Nanto S; Uematsu M
    J Endovasc Ther; 2014 Aug; 21(4):485-92. PubMed ID: 25101575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Endovascular Versus Bypass Surgery in Femoropopliteal TASC II D Lesions: A Single-Center Study.
    Veraldi GF; Mezzetto L; Macrì M; Criscenti P; Corvasce A; Poli R
    Ann Vasc Surg; 2018 Feb; 47():179-187. PubMed ID: 28943491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of statin therapy with the primary patency of femoral and popliteal artery stents.
    de Grijs D; Teixeira P; Katz S
    J Vasc Surg; 2018 May; 67(5):1472-1479. PubMed ID: 29224939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective Multicenter Comparison Between Viabahn Covered Stent-Grafts and Supera Interwoven Nitinol Stents for Endovascular Treatment in Severely Calcified Femoropopliteal Artery Disease: The ARMADILLO Study (Adjusted Retrospective coMparison of scAffolDs In caLcified LesiOns).
    Horie K; Takahara M; Nakama T; Tanaka A; Tobita K; Hayakawa N; Mori S; Iwata Y; Suzuki K
    J Endovasc Ther; 2024 Jun; 31(3):400-409. PubMed ID: 36146948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease.
    Mwipatayi BP; Perera K; Daneshmand A; Daniel R; Wong J; Thomas SD; Burrows SA
    Vascular; 2018 Feb; 26(1):3-11. PubMed ID: 28436316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of combined superficial femoral artery endovascular therapy with popliteal-to-distal bypass: A paradigm shift in surgical open bypass for chronic limb-threatening ischemia.
    Kobayashi T; Hamamoto M; Okazaki T; Hasegawa M; Fujiwara T; Takahashi S
    Vascular; 2021 Dec; 29(6):905-912. PubMed ID: 33349196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent.
    Soga Y; Iida O; Hirano K; Yokoi H; Nanto S; Nobuyoshi M
    J Vasc Surg; 2010 Sep; 52(3):608-15. PubMed ID: 20573476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Patency and Clinical Outcomes of Nitinol Stenting for Femoropopliteal Atherosclerotic Disease.
    Abdoli S; Katz S; Ochoa C
    Ann Vasc Surg; 2020 Jul; 66():566-572. PubMed ID: 31705987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of ePTFE/nitinol self-expanding stent graft vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease.
    McQuade K; Gable D; Hohman S; Pearl G; Theune B
    J Vasc Surg; 2009 Jan; 49(1):109-15, 116.e1-9; discussion 116. PubMed ID: 19028055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions.
    Bosiers M; Setacci C; De Donato G; Torsello G; Silveira PG; Deloose K; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Callaert J; Eckstein HH; Teβarek J; Giaquinta A; Wauters J
    J Endovasc Ther; 2020 Apr; 27(2):287-295. PubMed ID: 31997715
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and efficacy of antiplatelet/anticoagulation regimens after Viabahn stent graft treatment for femoropopliteal occlusive disease.
    Ullery BW; Tran K; Itoga N; Casey K; Dalman RL; Lee JT
    J Vasc Surg; 2015 Jun; 61(6):1479-88. PubMed ID: 25704407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Characteristics of In-Stent Restenosis After Drug-Eluting Stent Implantation in Femoropopliteal Lesions and 1-Year Prognosis After Repeat Endovascular Therapy for These Lesions.
    Iida O; Takahara M; Soga Y; Hirano K; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
    JACC Cardiovasc Interv; 2016 Apr; 9(8):828-834. PubMed ID: 27101908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term clinical and quality of life outcomes after stenting of femoropopliteal artery stenosis: 3-year results from the STROLL study.
    Bunte MC; Cohen DJ; Jaff MR; Gray WA; Magnuson EA; Li H; Feiring A; Cioppi M; Hibbard R; Gray B; Khatib Y; Jessup D; Patarca R; Du J; Stoll HP; Massaro J; Safley DM;
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):106-114. PubMed ID: 29521013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of femoropopliteal endovascular interventions on subsequent open bypass.
    Gifford SM; Fleming MD; Mendes BC; Stauffer KC; De Martino RR; Oderich GS; Gloviczki P; Bower TC
    J Vasc Surg; 2016 Sep; 64(3):623-8. PubMed ID: 27288105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1-Year Results of a Multicenter Randomized Controlled Trial Comparing Heparin-Bonded Endoluminal to Femoropopliteal Bypass.
    Reijnen MMPJ; van Walraven LA; Fritschy WM; Lensvelt MMA; Zeebregts CJ; Lemson MS; Wikkeling ORM; Smeets L; Holewijn S
    JACC Cardiovasc Interv; 2017 Nov; 10(22):2320-2331. PubMed ID: 29169500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitinol stent implantation for femoropopliteal disease in patients on hemodialysis: results of the 3-year retrospective multicenter APOLLON study.
    Fujihara M; Higashimori A; Kato Y; Taniguchi H; Iwasaki Y; Amano T; Sumiyoshi A; Nishiya D; Yokoi Y
    Heart Vessels; 2016 Sep; 31(9):1476-83. PubMed ID: 26337619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease.
    McQuade K; Gable D; Pearl G; Theune B; Black S
    J Vasc Surg; 2010 Sep; 52(3):584-90; discussion 590-1, 591.e1-591.e7. PubMed ID: 20598480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.